Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche May Grant Tamiflu Licensing Rights For Pandemic Use

This article was originally published in The Pink Sheet Daily

Executive Summary

Roche would consider working with governments and manufacturers to produce Tamiflu for stockpiling – but not commercial use – for a bird flu pandemic.

You may also be interested in...



Roche Agrees To Grant Tamiflu Manufacturing Rights To 15 Companies

Teva and Mylan are among the firms that have agreements with Roche to manufacture generic versions of the flu therapy.

Roche Agrees To Grant Tamiflu Manufacturing Rights To 15 Companies

Teva and Mylan are among the firms that have agreements with Roche to manufacture generic versions of the flu therapy.

Roche To Meet With Generic Firms On Tamiflu Rights After Intervention From Senators

Roche agrees to meet with Teva, Mylan, Ranbaxy and Barr to discuss granting manufacturing rights for Tamiflu in order to meet growing global demand for the avian flu antiviral.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS061121

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel